Radiopharmaceutical complexes and combinations

MX2026005511APending Publication Date: 2026-10-02BAYER AG +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: MX2026005511
Authority / Receiving Office: MX · MX
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-11-05
Filing Date: 2026-05-06
Publication Date: 2026-10-02

Application Information

Patent Timeline

05 Nov 2024

Priority

06 May 2026

Application

MX2026005511

02 Oct 2026

Publication

MX2026005511A

IPC: A61K51/10; A61P35/00; C07K16/28; C07K16/30; C07K16/32; C07K16/40

CPC: A61K51/1096; A61K51/1027; A61K51/1051; C07K16/28; A61P35/00; C07K2317/77; A61K2039/505; C07K16/32

Inventors: FENG Yuan Zeng; CRUCIANI Véronique

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to tissue-targeting compounds. In particular, the present invention relates to tissue-targeting compounds comprising a monoclonal antibody or an antigen-binding fragment thereof having binding affinity for HER2, GPC3, CEACAM5, TROP2, GUCY2C, cMet, FolRa, DLL3, Nectin-4 or STEAP1. Further, the present invention relates to combinations, preferably pharmaceutical combinations comprising a tissue-targeting compound of formula (I) and a further pharmaceutical agent. Said combinations are useful in therapy, preferably in treating hyperproliferative diseases such as cancer.

Need to check novelty before this filing date? Find Prior Art